Vaccination of Humans

Abstract

In 1796 Edward Jenner inoculated a young boy with cowpox infected material from cows then demonstrated that he was protected against a subsequent challenge with the variola agent smallpox. This is universally accepted as the first step in the development of the modern vaccination technique. For almost one century, vaccination meant take infectious agents or part of them, inactivate them using heat or chemical treatments and inoculate these products into humans. Modern techniques, such as recombinant deoxyribonucleic acid (DNA), polysaccharide conjugation and, more recently, the genomic approach, have allowed not only to obtain safer vaccines, but also to develop new products against those agents for which a vaccine had not been yet developed. Vaccines have been one of the most effective means of combating deadly infectious diseases in the near past and they will also become an important tool to fight some plagues of our time, such as tumours, chronic and autoimmune diseases and allergies.

Key Concepts:

  • People who survive an infectious disease, generally, do not develop the same disease again.

  • Vaccination means to expose the body to biological material that mimics the infectious agents giving protection without suffering disease.

  • Vaccines are the most effective tool to combat deadly infectious agents.

  • Combination vaccines are used to reduce the number of shots, especially in children.

  • Killed/inactivated infectious agents or part of them were the only vaccines used for most of the twentieth century.

  • Polysaccharide conjugation, recombinant DNA techniques and, more recently, reverse vaccinology have led the development of new generation vaccines.

  • Therapeutic vaccines will be used to fight chronic infectious diseases, cancers, neurodegenerative diseases, allergies and autoimmune diseases.

  • New delivery systems and new adjuvants will be developed to increment vaccineÔÇÉinduced immune response against many infectious agents.

Keywords: vaccines; infectious diseases; therapeutic vaccines; meningococcus

Figure 1.

Comparison between the conventional vaccinology and the reverse vaccinology approaches.

close

References

Berd D, Maguire HC Jr, Bloome E et al. (1998) Regression of lung metastases after immunotherapy with autologous, DNP‐modified melanoma vaccine. In: 34th Annual Meeting of the American Society of Clinical Oncology, vol. 17, 434 pp. Thomas Jefferson University, Philadelphia, Pennsylvania, USA.

Brander C and Walker BD (1999) T lymphocyte responses in HIV‐1 infection: implication for vaccine development. Current Opinion in Immunology 11(4): 451–459.

Fenner F, Henderson DA, Arita L et al. (1988) Smallpox and its Eradication. Geneva: World Health Organization.

Glenny AT and Hopkins BE (1923) Diphtheria toxoid as an immunizing agent. British Journal of Experimental Pathology 4: 283–288.

Goldschneider I, Gotschlich EC and Artenstein MS (1969) Human immunity to the meningococcus. The role of humoral antibodies. Journal of Experimental Medicine 129: 1307–1326.

McAleer WJ, Buynak EB, Maigetter RZ et al. (1984) Human hepatitis B vaccine from recombinant yeast. Nature 307: 178–180.

Pasteur L (1880) De l'attenuation du virus du cholèra des poules. Comptes Rendus de l'Academie des Sciences de Paris 91: 673–680.

Peppoloni S, Ruggiero P, Contorni M et al. (2003) Mutants of the E. coli heat‐labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines. Expert Review of Vaccines 2: 285–293.

Pizza M, Scarlato E, Masignani V et al. (2000) Identification of vaccine candidates against serogroup B meningococcus by whole‐genome sequencing. Science 287(5459): 1816–1820.

Plosker GL (2011) Sipuleucel‐T in metastatic castration‐resistant prostate cancer. Biodrugs 25: 255–256.

Rappuoli R, Pizza M, Covacci A et al. (1992) Recombinant acellular pertussis vaccine from the laboratory to the clinic: improving the quality of the immune response. FEMS Microbiology & immunology 4: 161–170.

Report of the Royal Commission (1928) The fatalities at Bundaberg. Medical Journal of Australia 2: 2–30, 38–63.

Schneerson R, Barrera O, Sutton A and Robbins JB (1980) Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide–protein conjugates. Journal of Experimental Medicine 152(2): 361–376.

Steams RP and Pasti G Jr (1950) Remarks upon the introduction of inoculation for smallpox in England. Bulletin of the History of Medicine 24: 103–122.

Vesikari T, Knuf M, Wutzler P et al. (2011) Oil‐in‐water emulsion adjuvant with influenza vaccine in young children. The New England Journal of Medicine 365(15): 1406–1416.

Further Reading

Levine MM, Dougan G, Good MF et al. (2010) New Generation Vaccines, 4th edn. New York: Informa Healthcare USA.

The Institute of Medicine. Immunization Safety Review: Vaccines and Autism. May 2004. Washington, DC: National Academy Press.

U.S. Department of Health and Human Services, National Institute of Health, National Institute of Allergy and Infectious Diseases (2007) The Jordan Report. Accelerated Development of Vaccines 2007. Bethesda, MD: NIH Publications (http://www.upmc‐biosecurity.org/website/resources/govt_docs/countermeasures/hhs/hhs_jordan_rpt_accel_dev_vac_2007.html).

WHO initiative for vaccine research (http://www.who.int/vaccine_research/diseases/alphabetical/en).

World Health Organization (1997) The CVI Strategic Plan. Managing Opportunity and Change: A Vision of Vaccination for the 21st Century. Geneva: WHO.

World Health Organization (2010) The World Health Report 2010: Health Systems Financing: The Path to Universal Coverage (http://www.who.int/whr/2010/en/index.html).

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Rappuoli, Rino, and Chiarot, Emiliano(Dec 2011) Vaccination of Humans. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0000961.pub3]